Literature DB >> 4054208

Dextropropoxyphene kinetics after single and repeated oral doses in man.

K Brøsen, L F Gram, J Schou, N E Larsen, P Thayssen.   

Abstract

The kinetics of dextropropoxyphene (DP) and its main metabolite norpropoxyphene (NP) were studied in 6 healthy male subjects after a single oral dose of 195 mg DP HCl, and during and after 12 daily single oral doses of 195 mg DP HCl. The kinetics varied up to five-fold between individuals after the single dose, the apparent mean elimination half-life (t1/2) was 16 h for DP and 29 h for NP. The mean apparent overall plasma clearance (CL) for DP was 2.61/min. There was no systematic difference in DP clearance between the single and multiple doses, but the accuracy of individual predictions from single to multiple doses was poor, probably because of imprecise determinations of the AUC and t1/2 in the single dose experiments. The individual correlation between single and multiple dose kinetics was good for NP, although the predicted plasma levels during steady state were significantly higher than the observed levels (mean AUCss/AUCsd: 0.81). There was no sign of saturation kinetics on repeated administration. In fact, autoinduction, resulting in significantly lower plasma concentrations after treatment for 1 week was found for NP and was indicated for DP. On discontinuing DP after 12 days of treatment, the apparent mean t1/2 of DP was 23 h and of NP 25 h.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4054208     DOI: 10.1007/BF00547373

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography.

Authors:  R L Wolen; E A Ziege; C M Gruber
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

2.  Plasma concentrations of propoxyphene in man. I. Following oral administration of the drug in solution and capsule forms.

Authors:  J G Wagner; P G Welling; S B Roth; E Sakmar; K P Lee; J E Walker
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1972-02

3.  D-propoxyphene kinetics in man: significance of a deep third compartment.

Authors:  L F Gram; K Schmidt; F N Christensen; J Schou
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo.

Authors:  D R Holland; M I Steinberg
Journal:  Toxicol Appl Pharmacol       Date:  1979-01       Impact factor: 4.219

5.  d-Propoxyphene single dose kinetics in a subject taking phenobarbital.

Authors:  L F Gram; J Schou; J Heltberg; W L Way
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-05

6.  Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals.

Authors:  R Nickander; S E Smits; M I Steinberg
Journal:  J Pharmacol Exp Ther       Date:  1977-01       Impact factor: 4.030

7.  d-Propoxyphene kinetics after single oral and intravenous doses in man.

Authors:  L F Gram; J Schou; W L Way; J Heltberg; N O Bodin
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

8.  Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits.

Authors:  H Lund-Jacobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-03

9.  Cardiovascular effect of imipramine and nortriptyline in elderly patients.

Authors:  P Thayssen; M Bjerre; P Kragh-Sørensen; M Møller; O L Petersen; C B Kristensen; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene.

Authors:  C E Inturrisi; W A Colburn; K Verebey; H E Dayton; G E Woody; C P O'Brien
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

View more
  2 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.